Clinical Trial Update: Intratumoral N17350 in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Update on the investigational intratumoral therapy N17350 being studied in advanced solid tumors in Phase 1 and Phase 2 trials, sponsored by Onchilles Pharma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Non-small Cell Lung Cancer
• Solid Tumors
• Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Skin
• Triple-negative Breast Cancer

Drugs mentioned

• N17350

Snippet

Sponsor: Onchilles Pharma Inc | Conditions: Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING